COST-EFFECTIVENESS ANALYSIS OF IPX066 IN ADVANCED PARKINSON'S DISEASE

被引：0
|
作者：
Arnold, R. J. [1 ]
Frasco, M. A. [1 ]
Layton, A. [1 ]
Rustay, N. R. [2 ]
Chen, S. [2 ]
机构：
[1] Quorum Consulting, San Francisco, CA USA
[2] Impax Labs Inc, Hayward, CA USA
来源：
VALUE IN HEALTH | 2015年 / 18卷 / 03期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PND31
引用
收藏
页码：S283 / S283
页数：1
相关论文
共 50 条
  • [1] Analysis of IPX066 Dosing Data in Advanced Parkinson's Disease (PD) Patients
    Hsu, Ann
    O'Connell, Martin
    Kell, Sherron
    Gupta, Suneel
    [J]. NEUROLOGY, 2013, 80
  • [2] Exploratory analysis of IPX066 on motor fluctuations in advanced Parkinson's disease (PD)
    Hsu, A.
    O'Connell, M.
    Khanna, S.
    Gupta, S.
    [J]. MOVEMENT DISORDERS, 2012, 27 : S122 - S122
  • [3] The Influence of Concomitant Medications on the Efficacy of IPX066 in Advanced Parkinson's Disease
    LeWitt, Peter A.
    Metman, Leo Verhagen
    Rubens, Robert
    Khanna, Sarita
    Kell, Sherron
    Gupta, Suneel
    [J]. ANNALS OF NEUROLOGY, 2015, 78 : S53 - S53
  • [4] Onset and Duration of Clinical Effect of IPX066 in Advanced Parkinson's Disease
    Ellenbogen, Aaron
    Hauser, Robert A.
    Modi, Nishit B.
    Hsu, Ann
    Khanna, Sarita
    Gupta, Suneel
    [J]. ANNALS OF NEUROLOGY, 2015, 78 : S48 - S48
  • [5] Crossover Comparison of IPX066 and a Standard Levodopa Formulation in Advanced Parkinson's Disease
    Hauser, Robert A.
    Ellenbogen, Aaron L.
    Metman, Leo Verhagen
    Hsu, Ann
    O'Connell, Martin J.
    Modi, Nishit B.
    Yao, Hsuan-Ming
    Kell, Sherron H.
    Gupta, Suneel K.
    [J]. MOVEMENT DISORDERS, 2011, 26 (12) : 2246 - 2252
  • [6] Conversion to IPX066 from Standard Levodopa Formulations in Advanced Parkinson's Disease: Experience in Clinical Trials
    Nausieda, Paul A.
    Hsu, Ann
    Elmer, Lawrence
    Gil, Ramon A.
    Spiegel, Joerg
    Singer, Carlos
    Khanna, Sarita
    Rubens, Robert
    Kell, Sherron
    Modi, Nishit B.
    Gupta, Suneel
    [J]. JOURNAL OF PARKINSONS DISEASE, 2015, 5 (04) : 837 - 845
  • [7] Dose conversion to IPX066 in advanced Parkinson's disease patients treated with carbidopa-levodopa-entacapone
    Hsu, A.
    Khanna, S.
    Kell, S.
    Espay, A.
    Gil, R.
    Singer, C.
    Gupta, S.
    [J]. MOVEMENT DISORDERS, 2013, 28 : S149 - S149
  • [8] Randomized trial of IPX066, carbidopa/levodopa extended release, in early Parkinson's disease
    Pahwa, Rajesh
    Lyons, Kelly E.
    Hauser, Robert A.
    Fahn, Stanley
    Jankovic, Joseph
    Pourcher, Emmanuelle
    Hsu, Ann
    O'Connell, Martin
    Kell, Sherron
    Gupta, Suneel
    [J]. PARKINSONISM & RELATED DISORDERS, 2014, 20 (02) : 142 - 148
  • [9] Comparative efficacy and safety of a novel carbidopa-levodopa product (IPX066) and Sinemet in advanced Parkinson's disease
    Ellenbogen, A.
    Hauser, R.
    Omidvar, O.
    Hsu, A.
    O'Connell, M.
    Kell, S.
    Gupta, S.
    [J]. PARKINSONISM & RELATED DISORDERS, 2009, 15 : S126 - S126
  • [10] Efficacy of IPX066, extended-release levodopa-carbidopa in patients with advanced Parkinson's disease: Responder analyses
    Gupta, Suneel
    Khanna, Sarita
    Rustay, Nathan
    Rubens, Robert
    Kell, Sherron
    [J]. MOVEMENT DISORDERS, 2017, 32 : S36 - S36
12345